Key Developments: Catalyst Pharmaceutical Partners Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

4.20USD
30 Mar 2015
Change (% chg)

$0.01 (+0.24%)
Prev Close
$4.19
Open
$4.20
Day's High
$4.36
Day's Low
$4.05
Volume
512,876
Avg. Vol
777,122
52-wk High
$5.10
52-wk Low
$1.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceuticals announces FDA Orphan Drug Designation of Firdapse for Treatment of Congenital Myasthenic Syndromes
Thursday, 5 Mar 2015 10:35am EST 

Catalyst Pharmaceutical Partners Inc:Says the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for Firdapse(tm) for treatment of patients with Congenital Myasthenic Syndromes (CMS).  Full Article

Catalyst Pharmaceutical Partners Inc announces closing of previously announced public offering
Monday, 9 Feb 2015 10:10am EST 

Catalyst Pharmaceutical Partners Inc:Closes its public offering of shares of its common stock.Sold 11,500,000 shares of its common stock in the offering, which includes 1,500,000 shares that were issued upon the full exercise by the underwriters of their over-allotment option.Offering price was $3.25 per share, and the net proceeds from the sale of the shares is expected to be about $34.7 mln.Piper Jaffray & Co. acted as the sole lead book-running manager and SunTrust Robinson Humphrey acted as the passive book-running manager with respect to this offering.Further, Roth Capital Partners and H.C. Wainwright & Co. acted as the lead co-manager and co-manager, respectively.  Full Article

Catalyst Pharmaceutical Partners Inc. prices public offering of common stock
Wednesday, 4 Feb 2015 09:00am EST 

Catalyst Pharmaceutical Partners Inc:Pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at an offering price of $3.25 per share.In connection with the offering, Catalyst has also granted the underwriters 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.Net proceeds from the sale of the shares by Catalyst after underwriting discounts and commissions and other offering expenses are expected to be about $30.1 mln.Catalyst plans to use the net proceeds from the offering to pay milestone payments due on final approval of an NDA for Firdapse; to pay pre commercialization and other expenses required to launch Firdapse.Also uses to fund future clinical studies of Firdapse for other indications, to the extent that such additional studies are required; to fund future clinical and nonclinical studies of CPP-115; and for general corporate purposes.The offering is subject to customary closing conditions and is expected to close on Feb. 9.Piper Jaffray & Co. is acting as the sole lead book-running manager and SunTrust Robinson Humphrey is acting as the passive book-running manager with respect to this offering.Further, Roth Capital Partners and H.C. Wainwright & Co. are acting as the lead co-manager and co-manager, respectively.  Full Article

Catalyst Pharmaceutical Partners Inc announces commencement of public offering of common stock
Tuesday, 3 Feb 2015 04:40pm EST 

Catalyst Pharmaceutical Partners Inc:Intends to offer shares of its common stock in a public offering.Also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any.Plans to use the net proceeds from the offering to pay milestone payments due on final approval of an NDA for Firdapse, to pay pre-commercialization and other expenses required to launch Firdapse.Also uses to fund future clinical studies of Firdapse for other indications, to the extent that such additional studies are required.Also to fund future clinical and nonclinical studies of CPP-115 and for general corporate purposes.Piper Jaffray & Co. is acting as the sole lead book-running manager and SunTrust Robinson Humphrey is acting as the passive book-running manager.  Full Article

Catalyst Pharmaceuticals Partners Inc proposes settlement of pending securities class action lawsuit
Tuesday, 4 Nov 2014 08:03am EST 

Catalyst Pharmaceuticals Partners Inc:Says that it has entered into a memorandum of understanding to settle its pending class action securities lawsuit.As previously disclosed, the company and one of its executive officers are defendants in a class action lawsuit filed in the U.S. District Court for the Southern District of Florida.Amended complaint purports to state a claim for alleged misrepresentations regarding the development of Firdapse(tm) on behalf of a class of those who purchased shares of the company's common stock between Aug. 27, 2013 and Oct. 18, 2013.  Full Article

Catalyst Pharmaceuticals Partners Inc announces positive top-line Phase 3 data from Pivotal Firdapse clinical trial
Monday, 29 Sep 2014 04:03pm EDT 

Catalyst Pharmaceuticals Partners Inc:Says positive top-line results from the pivotal Phase 3 clinical trial of Firdapse (amifampridine phosphate tablets equivalent to 10 mg amifampridine) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS).Both co-primary endpoints, quantitative myasthenia gravis score (QMG) and subject global impression (SGI), demonstrated that Firdapse was significantly superior to placebo, as did a secondary endpoint for the physician's clinical global impression of improvement.  Full Article

Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
Tuesday, 2 Sep 2014 08:03am EDT 

Catalyst Pharmaceutical Partners Inc:Says initiation of its second Phase 1 safety and tolerance study for CPP-115, a novel GABA aminotransferase (GABA-AT) inhibitor.Phase 1(b) trial is designed in 2 parts to evaluate the safety and tolerability of single and multiple doses of CPP-115, including CNS side effects, and respiratory and cardiovascular safety.  Full Article

Catalyst Pharmaceutical Partners Inc announces closing of public offering
Tuesday, 8 Apr 2014 10:30am EDT 

Catalyst Pharmaceutical Partners Inc:Closes public offering of shares of common stock.Company sold 13,023,750 shares of common stock in offering, including 1,698,750 shares that were issued upon exercise by underwriters of their overallotment option.Offering price was $2.21 per share, and net proceeds from sale of shares is expected to be $26.8 mln.Piper Jaffray & Co. acted as sole book-running manager for offering, Roth Capital Partners acted as co-lead manager, and H.C. Wainwright & Co., LLC acted as co-manager with respect to offering.  Full Article

Catalyst Pharmaceutical Partners prices public offering of common stock
Thursday, 3 Apr 2014 09:00am EDT 

Catalyst Pharmaceutical Partners Inc:Prices underwritten public offering of 11,325,000 shares of common stock at $2.21 per share.Grantes underwriters a 30-day option to purchase up to an additional 1,698,750 shares to cover over-allotments.Expects net proceeds to be about $23.3 mln.To use net proceeds for development of Firdapse or LEMS for pre-commercialization activities relating to Firdapse, for development of CPP-115 and for general corporate purposes.Expected to close on April 8.Piper Jaffray & Co is sole book-running manager.Roth Capital Partners co-lead manager.H.C. Wainwright & Co LLC is co-manager.  Full Article

Catalyst Pharmaceutical Partners Inc announces commencement of public offering of common stock
Wednesday, 2 Apr 2014 04:04pm EDT 

Catalyst Pharmaceutical Partners Inc:Intends to offer shares of its common stock in a public offering.Plans to use net proceeds from offering for continuing development of Firdapse for treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS.For pre-commercialization activities relating to Firdapse.Forcontinuing development of CPP-115and for general corporate purposes.Piper Jaffray & Co. is acting as the sole book-running manager.  Full Article

Search Stocks